FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3136167138> ?p ?o ?g. }

• W3136167138 endingPage "1037" @default.
• W3136167138 startingPage "1028" @default.
• W3136167138 abstract "Paroxysmal nocturnal hemoglobinuria (PNH) is a rare, acquired disease characterized by chronic complement-mediated hemolysis. C5 inhibition controls intravascular hemolysis in untreated PNH but cannot address extravascular hemolysis. Pegcetacoplan, a pegylated peptide targeting proximal complement protein C3, potentially inhibits both intravascular and extravascular hemolysis.We conducted a phase 3 open-label, controlled trial to assess the efficacy and safety of pegcetacoplan as compared with eculizumab in adults with PNH and hemoglobin levels lower than 10.5 g per deciliter despite eculizumab therapy. After a 4-week run-in phase in which all patients received pegcetacoplan plus eculizumab, we randomly assigned patients to subcutaneous pegcetacoplan monotherapy (41 patients) or intravenous eculizumab (39 patients). The primary end point was the mean change in hemoglobin level from baseline to week 16. Additional clinical and hematologic markers of hemolysis and safety were assessed.Pegcetacoplan was superior to eculizumab with respect to the change in hemoglobin level from baseline to week 16, with an adjusted (least squares) mean difference of 3.84 g per deciliter (P<0.001). A total of 35 patients (85%) receiving pegcetacoplan as compared with 6 patients (15%) receiving eculizumab no longer required transfusions. Noninferiority of pegcetacoplan to eculizumab was shown for the change in absolute reticulocyte count but not for the change in lactate dehydrogenase level. Functional Assessment of Chronic Illness Therapy-Fatigue scores improved from baseline in the pegcetacoplan group. The most common adverse events that occurred during treatment in the pegcetacoplan and eculizumab groups were injection site reactions (37% vs. 3%), diarrhea (22% vs. 3%), breakthrough hemolysis (10% vs. 23%), headache (7% vs. 23%), and fatigue (5% vs. 15%). There were no cases of meningitis in either group.Pegcetacoplan was superior to eculizumab in improving hemoglobin and clinical and hematologic outcomes in patients with PNH by providing broad hemolysis control, including control of intravascular and extravascular hemolysis. (Funded by Apellis Pharmaceuticals; PEGASUS ClinicalTrials.gov, NCT03500549.)." @default.
• W3136167138 created "2021-03-29" @default.
• W3136167138 creator A5015511458 @default.
• W3136167138 creator A5017262639 @default.
• W3136167138 creator A5021004681 @default.
• W3136167138 creator A5031046212 @default.
• W3136167138 creator A5033644240 @default.
• W3136167138 creator A5036495565 @default.
• W3136167138 creator A5038567234 @default.
• W3136167138 creator A5042150873 @default.
• W3136167138 creator A5047631289 @default.
• W3136167138 creator A5049668306 @default.
• W3136167138 creator A5051544503 @default.
• W3136167138 creator A5056971594 @default.
• W3136167138 creator A5064820220 @default.
• W3136167138 creator A5068820436 @default.
• W3136167138 creator A5069634051 @default.
• W3136167138 creator A5075001232 @default.
• W3136167138 creator A5087550018 @default.
• W3136167138 creator A5087938880 @default.
• W3136167138 creator A5091043028 @default.
• W3136167138 date "2021-03-18" @default.
• W3136167138 modified "2023-10-16" @default.
• W3136167138 title "Pegcetacoplan versus Eculizumab in Paroxysmal Nocturnal Hemoglobinuria" @default.
• W3136167138 cites W1529108748 @default.
• W3136167138 cites W1717575538 @default.
• W3136167138 cites W1970511662 @default.
• W3136167138 cites W2032628053 @default.
• W3136167138 cites W2038962823 @default.
• W3136167138 cites W2059419199 @default.
• W3136167138 cites W2078957722 @default.
• W3136167138 cites W2081653014 @default.
• W3136167138 cites W2081978633 @default.
• W3136167138 cites W2109533208 @default.
• W3136167138 cites W2127290864 @default.
• W3136167138 cites W2134558721 @default.
• W3136167138 cites W2145490488 @default.
• W3136167138 cites W2171068466 @default.
• W3136167138 cites W2198426544 @default.
• W3136167138 cites W2209557348 @default.
• W3136167138 cites W2274448549 @default.
• W3136167138 cites W2298789261 @default.
• W3136167138 cites W2323202050 @default.
• W3136167138 cites W2330809941 @default.
• W3136167138 cites W2616618502 @default.
• W3136167138 cites W2914587352 @default.
• W3136167138 cites W2959393635 @default.
• W3136167138 cites W3022268070 @default.
• W3136167138 doi "https://doi.org/10.1056/nejmoa2029073" @default.
• W3136167138 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33730455" @default.
• W3136167138 hasPublicationYear "2021" @default.
• W3136167138 type Work @default.
• W3136167138 sameAs 3136167138 @default.
• W3136167138 citedByCount "157" @default.
• W3136167138 countsByYear W31361671382021 @default.
• W3136167138 countsByYear W31361671382022 @default.
• W3136167138 countsByYear W31361671382023 @default.
• W3136167138 crossrefType "journal-article" @default.
• W3136167138 hasAuthorship W3136167138A5015511458 @default.
• W3136167138 hasAuthorship W3136167138A5017262639 @default.
• W3136167138 hasAuthorship W3136167138A5021004681 @default.
• W3136167138 hasAuthorship W3136167138A5031046212 @default.
• W3136167138 hasAuthorship W3136167138A5033644240 @default.
• W3136167138 hasAuthorship W3136167138A5036495565 @default.
• W3136167138 hasAuthorship W3136167138A5038567234 @default.
• W3136167138 hasAuthorship W3136167138A5042150873 @default.
• W3136167138 hasAuthorship W3136167138A5047631289 @default.
• W3136167138 hasAuthorship W3136167138A5049668306 @default.
• W3136167138 hasAuthorship W3136167138A5051544503 @default.
• W3136167138 hasAuthorship W3136167138A5056971594 @default.
• W3136167138 hasAuthorship W3136167138A5064820220 @default.
• W3136167138 hasAuthorship W3136167138A5068820436 @default.
• W3136167138 hasAuthorship W3136167138A5069634051 @default.
• W3136167138 hasAuthorship W3136167138A5075001232 @default.
• W3136167138 hasAuthorship W3136167138A5087550018 @default.
• W3136167138 hasAuthorship W3136167138A5087938880 @default.
• W3136167138 hasAuthorship W3136167138A5091043028 @default.
• W3136167138 hasBestOaLocation W31361671381 @default.
• W3136167138 hasConcept C111684460 @default.
• W3136167138 hasConcept C126322002 @default.
• W3136167138 hasConcept C159654299 @default.
• W3136167138 hasConcept C203014093 @default.
• W3136167138 hasConcept C2777346216 @default.
• W3136167138 hasConcept C2777991916 @default.
• W3136167138 hasConcept C2778639011 @default.
• W3136167138 hasConcept C2778917026 @default.
• W3136167138 hasConcept C2779902561 @default.
• W3136167138 hasConcept C71924100 @default.
• W3136167138 hasConcept C90924648 @default.
• W3136167138 hasConceptScore W3136167138C111684460 @default.
• W3136167138 hasConceptScore W3136167138C126322002 @default.
• W3136167138 hasConceptScore W3136167138C159654299 @default.
• W3136167138 hasConceptScore W3136167138C203014093 @default.
• W3136167138 hasConceptScore W3136167138C2777346216 @default.
• W3136167138 hasConceptScore W3136167138C2777991916 @default.
• W3136167138 hasConceptScore W3136167138C2778639011 @default.
• W3136167138 hasConceptScore W3136167138C2778917026 @default.
• W3136167138 hasConceptScore W3136167138C2779902561 @default.

• next